Related Experiment Videos
Clinical efficacy and safety of cefmenoxime in children
Insights
Cefmenoxime showed promising results in pediatric infections, with 88% of patients responding clinically. This new cephalosporin effectively treated various infections and eradicated pathogens in most cases.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Pharmacology
Background:
- Cefmenoxime is an investigational semisynthetic cephalosporin.
- Pediatric infections require effective and safe therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of cefmenoxime in pediatric patients.
- To assess clinical response and pathogen eradication rates.
Main Methods:
- A total of 18 pediatric patients with diverse infections were enrolled.
- Clinical signs, symptoms, and pathogen eradication were monitored.
- Serum peak levels and adverse events were recorded.
Main Results:
- 16 out of 18 (88%) patients showed a satisfactory clinical response.
- 12 out of 18 (67%) patients achieved pathogen eradication.
- 16 isolated pathogens were susceptible to cefmenoxime; one patient experienced a mild rash.
Conclusions:
- Cefmenoxime demonstrated significant clinical efficacy and good tolerability in pediatric patients.
- The study supports cefmenoxime as a potential treatment for various pediatric infections.
Abstract:
Cefmenoxime, an investigational semisynthetic cephalosporin, was evaluated in 18 pediatric patients with a variety of infections. There were seven patients with urinary tract infections, two with wound infections, two with osteomyelitis, two with abscess infections, one with cervical adenitis, one with hidradenitis, one with pneumonia and sepsis, one with periorbital cellulitis, and one with ventriculitis. A total of 16 (88%) patients had a satisfactory clinical response demonstrated by improvement in clinical signs and symptoms. A total of 12 (67%) patients demonstrated eradication of their infecting organisms. Of the pathogens isolated in these patients, 16 isolates were susceptible to cefmenoxime. One patient developed a generalized urticarial rash that resolved within 24 h after cessation of cefmenoxime therapy. Mean peak level in serum after intravenous infusion was 55 micrograms/ml.